Show simple item record

dc.contributor.authorHales, Charlotte
dc.contributor.authorTaylor, Peter N.
dc.contributor.authorChannon, Sue
dc.contributor.authorParadice, Ruth
dc.contributor.authorMcEwan, Kirsten
dc.contributor.authorZhang, Lei
dc.contributor.authorGyedu, Michael
dc.contributor.authorBakhsh, Ameen
dc.contributor.authorOkosieme, Onyebuchi
dc.contributor.authorMuller, Ilaria
dc.contributor.authorDraman, Mohd S.
dc.contributor.authorGregory, John W.
dc.contributor.authorDayan, Colin
dc.contributor.authorLazarus, John H.
dc.contributor.authorRees, D Aled
dc.contributor.authorLudgate, Marian
dc.date.accessioned2018-07-27T14:15:20Z
dc.date.available2018-07-27T14:15:20Z
dc.date.issued2018-01-15
dc.identifier.citationHales, C. et al (2018) 'Controlled Antenatal Thyroid Screening II: Effect of Treating Maternal Suboptimal Thyroid Function on Child Cognition', The Journal of Clinical Endocrinology & Metabolism, 103 (4):1583.en
dc.identifier.issn0021972X
dc.identifier.doi10.1210/jc.2017-02378
dc.identifier.urihttp://hdl.handle.net/10545/622840
dc.description.abstractContext and Objective The Controlled Antenatal Thyroid Screening (CATS) study investigated treatment of suboptimal gestational thyroid function (SGTF) on childhood cognition and found no difference in intelligence quotient (IQ) at 3 years between children of treated and untreated SGTF mothers. We have measured IQ in the same children at age 9.5 years and included children from normal gestational thyroid function (normal-GTF) mothers. Design, Setting, and Participants One examiner, blinded to participant group, assessed children’s IQ (Wechsler Intelligence Scale for Children, Fourth Edition UK), long-term memory, and motor function (Developmental Neuropsychological Assessment II) from children of 119 treated and 98 untreated SGTF mothers plus children of 232 mothers with normal-GTF. Logistic regression explored the odds and percentages of an IQ < 85 in the groups. Results There was no difference in IQ < 85 between children of mothers with normal-GTF and combined SGTF, i.e., treated and untreated (fully adjusted odds ratio [OR] = 1.15 [95% confidence interval (CI) 0.52, 2.51]; P = 0.731). Furthermore, there was no significant effect of treatment [untreated OR = 1.33 (95% CI 0.53, 3.34); treated OR = 0.75 (95% CI 0.27, 2.06) P = 0.576]. IQ < 85 was 6.03% in normal-GTF, 7.56% in treated, and 11.22% in untreated groups. Analyses accounting for treated-SGTF women with free thyroxine > 97.5th percentile of the entire CATS-I cohort revealed no significant effect on a child’s IQ < 85 in CATS-II. IQ at age 3 predicted IQ at age 9.5 (P < 0.0001) and accounted for 45% of the variation. Conclusions Maternal thyroxine during pregnancy did not improve child cognition at age 9.5 years. Our findings confirmed CATS-I and suggest that the lack of treatment effect may be a result of the similar proportion of IQ < 85 in children of women with normal-GTF and SGTF.
dc.description.sponsorshipN/Aen
dc.language.isoenen
dc.publisherOxford Academicen
dc.relation.urlhttps://academic.oup.com/jcem/article/103/4/1583/4802113en
dc.relation.urlhttps://orca-mwe.cf.ac.uk/109041/1/Binder1.pdf
dc.rightsArchived with thanks to The Journal of Clinical Endocrinology & Metabolismen
dc.subjectThyroiden
dc.subjectChildrenen
dc.titleControlled antenatal thyroid screening II: Effect of treating maternal suboptimal thyroid function on child cognition.en
dc.typeArticleen
dc.identifier.eissn19457197
dc.contributor.departmentCardiff Universityen
dc.identifier.journalThe Journal of Clinical Endocrinology & Metabolismen
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionCentre for Trials Research, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSt David’s Hospital, Cardiff and Vale University Health Board, Cardiff, Wales, United Kingdom
dc.contributor.institutionCentre for Trials Research, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionNeuroscience and Mental Health Research Institute, Cardiff University, Cardiff, Wales, United Kingdom
dc.contributor.institutionSchool of Medicine, Cardiff University, Cardiff, Wales, United Kingdom
html.description.abstractContext and Objective The Controlled Antenatal Thyroid Screening (CATS) study investigated treatment of suboptimal gestational thyroid function (SGTF) on childhood cognition and found no difference in intelligence quotient (IQ) at 3 years between children of treated and untreated SGTF mothers. We have measured IQ in the same children at age 9.5 years and included children from normal gestational thyroid function (normal-GTF) mothers. Design, Setting, and Participants One examiner, blinded to participant group, assessed children’s IQ (Wechsler Intelligence Scale for Children, Fourth Edition UK), long-term memory, and motor function (Developmental Neuropsychological Assessment II) from children of 119 treated and 98 untreated SGTF mothers plus children of 232 mothers with normal-GTF. Logistic regression explored the odds and percentages of an IQ < 85 in the groups. Results There was no difference in IQ < 85 between children of mothers with normal-GTF and combined SGTF, i.e., treated and untreated (fully adjusted odds ratio [OR] = 1.15 [95% confidence interval (CI) 0.52, 2.51]; P = 0.731). Furthermore, there was no significant effect of treatment [untreated OR = 1.33 (95% CI 0.53, 3.34); treated OR = 0.75 (95% CI 0.27, 2.06) P = 0.576]. IQ < 85 was 6.03% in normal-GTF, 7.56% in treated, and 11.22% in untreated groups. Analyses accounting for treated-SGTF women with free thyroxine > 97.5th percentile of the entire CATS-I cohort revealed no significant effect on a child’s IQ < 85 in CATS-II. IQ at age 3 predicted IQ at age 9.5 (P < 0.0001) and accounted for 45% of the variation. Conclusions Maternal thyroxine during pregnancy did not improve child cognition at age 9.5 years. Our findings confirmed CATS-I and suggest that the lack of treatment effect may be a result of the similar proportion of IQ < 85 in children of women with normal-GTF and SGTF.


This item appears in the following Collection(s)

Show simple item record